• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大精神病学相关的药物遗传学检测选择:加拿大精神病学相关的药物遗传学检测选择。

Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.

机构信息

The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada.

Department of Psychiatry, University of Calgary, Alberta, Canada.

出版信息

Can J Psychiatry. 2020 Aug;65(8):521-530. doi: 10.1177/0706743720904820. Epub 2020 Feb 17.

DOI:10.1177/0706743720904820
PMID:32064906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7492886/
Abstract

OBJECTIVE

To identify and assess pharmacogenetic testing options relevant to psychiatry in Canada.

METHOD

Searches of published literature, websites, and Standard Council of Canada's Laboratory Directory were conducted to identify pharmacogenetic tests available in Canada. Identified tests were assessed on 8 key questions related to analytical validity, accessibility, test ordering, delivery of test results, turnaround time, cost, clinical trial evidence, and gene/allele content.

RESULTS

A total of 13 pharmacogenetic tests relevant to psychiatry in Canada were identified. All tests were highly accessible, and most were conducted in accredited laboratories. Both direct-to-consumer and clinician-gated testing were identified, with turnaround times and cost ranging from 2 to 40 days and CAD$199 to CAD$2310, respectively. Two tests were supported by randomized controlled trials. All tests met minimum gene and allele panel recommendations for psychiatry, but no 2 panels were identical. No test was unequivocally superior to all other tests.

CONCLUSIONS

Pharmacogenetic testing in Canada is readily available but highly variable in terms of ordering procedures, delivery of results, turnaround times, cost, and gene/allele content. As such, it is important for psychiatrists and other health-care providers to understand the differences between the available tests to ensure appropriate selection and implementation within their practice.

摘要

目的

确定并评估加拿大精神病学相关的遗传药理学检测选项。

方法

通过检索已发表的文献、网站以及加拿大标准协会的实验室名录,确定加拿大可用的遗传药理学检测方法。针对分析有效性、可及性、检测订购、检测结果传递、周转时间、成本、临床试验证据和基因/等位基因内容这 8 个关键问题,对所确定的检测方法进行评估。

结果

共确定了 13 项加拿大精神病学相关的遗传药理学检测方法。所有检测均具有高度可及性,且大多数检测均在认可的实验室中进行。既鉴定了面向消费者的直接检测,也鉴定了由临床医生把关的检测,其周转时间和成本分别为 2 至 40 天和 CAD$199 至 CAD$2310。两项检测得到了随机对照试验的支持。所有检测均符合精神病学的最低基因和等位基因面板推荐标准,但没有两个面板是完全相同的。没有一种检测在所有方面都明显优于其他检测。

结论

加拿大的遗传药理学检测方法广泛可用,但在订购程序、结果传递、周转时间、成本和基因/等位基因内容方面存在高度差异。因此,精神病医生和其他医疗保健提供者了解可用检测方法之间的差异非常重要,以确保在其实践中进行适当的选择和实施。

相似文献

1
Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.加拿大精神病学相关的药物遗传学检测选择:加拿大精神病学相关的药物遗传学检测选择。
Can J Psychiatry. 2020 Aug;65(8):521-530. doi: 10.1177/0706743720904820. Epub 2020 Feb 17.
2
Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.迈向精神医学中药物遗传学的整合:一个最低限度、基于证据的基因检测面板。
Curr Opin Psychiatry. 2019 Jan;32(1):7-15. doi: 10.1097/YCO.0000000000000465.
3
Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.精神科商业药物遗传学检测的系统评价:聚焦CYP2D6和CYP2C19等位基因覆盖范围及结果报告
Pharmacogenet Genomics. 2017 Nov;27(11):387-393. doi: 10.1097/FPC.0000000000000303.
4
Re: Pharmacogenetic Testing Options Relevant to Psychiatry in Canada.关于:加拿大与精神病学相关的药物遗传学检测选项。
Can J Psychiatry. 2020 Aug;65(8):584-585. doi: 10.1177/0706743720925735. Epub 2020 May 13.
5
Pharmacogenetic testing in psychiatry: a review of features and clinical realities.精神病学中的药物遗传学检测:特征与临床现状综述
Clin Lab Med. 2008 Dec;28(4):599-617. doi: 10.1016/j.cll.2008.05.003.
6
Pharmacogenetics in psychiatric care, a call for uptake of available applications.精神科医疗中的药物遗传学:呼吁采用现有应用
Psychiatry Res. 2020 Oct;292:113336. doi: 10.1016/j.psychres.2020.113336. Epub 2020 Jul 27.
7
[Pharmacogenetics in psychiatry: how far are we from clinical application?].[精神病学中的药物遗传学:我们离临床应用还有多远?]
Vertex. 2012 Jul-Aug;23(104):299-309.
8
"Black box" pharmacogenetic decision-support tools in psychiatry.精神病学中的“黑匣子”药物遗传学决策支持工具。
Braz J Psychiatry. 2020 Apr;42(2):113-115. doi: 10.1590/1516-4446-2019-0724. Epub 2020 Jan 24.
9
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.将药物遗传学检测整合到儿童精神病诊所中的可接受性、可行性和实用性。
Clin Transl Sci. 2021 Mar;14(2):589-598. doi: 10.1111/cts.12914. Epub 2020 Nov 9.
10
The use of pharmacogenetic testing in psychiatry.精神医学中的药物遗传学检测的应用。
J Am Assoc Nurse Pract. 2021 Nov 10;33(11):849-851. doi: 10.1097/JXX.0000000000000666.

引用本文的文献

1
Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study.加拿大安大略省基层医疗中抗抑郁药物处方的药物基因组学(PGx)检测的关键信息提供者观点:一项定性描述研究
BMJ Open. 2025 Aug 27;15(8):e091562. doi: 10.1136/bmjopen-2024-091562.
2
Normalising the Implementation of Pharmacogenomic (PGx) Testing in Adult Mental Health Settings: A Theory-Based Systematic Review.使成人心理健康环境中药基因组学(PGx)检测的实施标准化:基于理论的系统评价。
J Pers Med. 2024 Sep 27;14(10):1032. doi: 10.3390/jpm14101032.
3
Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic.精神科诊所实施药物遗传学检测的方法与障碍
PCN Rep. 2022 Jun 22;1(2):e26. doi: 10.1002/pcn5.26. eCollection 2022 Jun.
4
Patient perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care: a qualitative description study.基层医疗中患者对抗抑郁药物处方进行药物基因组学(PGx)检测的看法:一项定性描述性研究。
J Community Genet. 2024 Jun;15(3):293-309. doi: 10.1007/s12687-024-00705-y. Epub 2024 Apr 8.
5
A Canadian Simulation Model for Major Depressive Disorder: Study Protocol.加拿大重度抑郁症模拟模型:研究方案。
Pharmacoecon Open. 2024 May;8(3):493-505. doi: 10.1007/s41669-024-00481-y. Epub 2024 Mar 26.
6
Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: A systematic review.药剂师和药学专业学生对药物基因组学的知识、认知和态度:一项系统综述。
Health Sci Rep. 2024 Jan 25;7(1):e1844. doi: 10.1002/hsr2.1844. eCollection 2024 Jan.
7
Moving towards the implementation of pharmacogenetic testing in Quebec.迈向魁北克药物遗传学检测的实施。
Front Genet. 2024 Jan 3;14:1295963. doi: 10.3389/fgene.2023.1295963. eCollection 2023.
8
The role of pharmacogenetics in the treatment of major depressive disorder: a critical review.药物遗传学在重度抑郁症治疗中的作用:一项批判性综述。
Front Psychiatry. 2023 Nov 10;14:1307473. doi: 10.3389/fpsyt.2023.1307473. eCollection 2023.
9
The Potential Roles of Pharmacists in the Clinical Implementation of Pharmacogenomics.药剂师在药物基因组学临床应用中的潜在作用。
Pharmacy (Basel). 2023 Nov 19;11(6):180. doi: 10.3390/pharmacy11060180.
10
Cost-effectiveness of pharmacogenomic-guided treatment for major depression.基于基因组学的抗抑郁治疗的成本效益分析。
CMAJ. 2023 Nov 14;195(44):E1499-E1508. doi: 10.1503/cmaj.221785.

本文引用的文献

1
Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection.探索药物遗传学检测的迷宫:检测选择指南
Clin Pharmacol Ther. 2019 Aug;106(2):309-312. doi: 10.1002/cpt.1432. Epub 2019 Apr 20.
2
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?在临床实践中,确定实施药物基因组学的价值是否需要随机对照试验?
Clin Pharmacol Ther. 2019 Aug;106(2):284-286. doi: 10.1002/cpt.1420. Epub 2019 Apr 12.
3
Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?精神科的商业药物遗传学检测:它们是否有助于实施药物遗传学给药指南?
Pharmacopsychiatry. 2020 Jul;53(4):174-178. doi: 10.1055/a-0863-4692. Epub 2019 Mar 21.
4
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.临床药物遗传学实施联盟 CYP2D6 基因分型和托莫西汀治疗指南
Clin Pharmacol Ther. 2019 Jul;106(1):94-102. doi: 10.1002/cpt.1409. Epub 2019 Apr 13.
5
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.在 GUIDED 试验中,药物基因组学对重度抑郁症临床结局的影响:一项大型、患者和评定者设盲、随机、对照研究。
J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.
6
Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.基于随机对照试验的荟萃分析:药物遗传学检测与抑郁症状缓解。
Pharmacogenomics. 2019 Jan;20(1):37-47. doi: 10.2217/pgs-2018-0142. Epub 2018 Dec 6.
7
Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.迈向精神医学中药物遗传学的整合:一个最低限度、基于证据的基因检测面板。
Curr Opin Psychiatry. 2019 Jan;32(1):7-15. doi: 10.1097/YCO.0000000000000465.
8
The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.基于药物基因组学检测对治疗重度抑郁症急性期反应和缓解率的影响:一项荟萃分析。
J Affect Disord. 2018 Dec 1;241:484-491. doi: 10.1016/j.jad.2018.08.056. Epub 2018 Aug 14.
9
Professional opportunity for pharmacists to integrate pharmacogenomics in medication therapy.药剂师将药物基因组学整合到药物治疗中的职业机会。
Can Pharm J (Ott). 2018 Apr 2;151(3):167-169. doi: 10.1177/1715163518766376. eCollection 2018 May-Jun.
10
Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.商业性基于药物遗传学的决策支持工具之间的基因型、表型和用药推荐一致性
Pharmacogenomics J. 2018 Sep;18(5):613-622. doi: 10.1038/s41397-018-0027-3. Epub 2018 May 25.